OVERVIEW
Intrastromal corneal ring segments (ICRS) are composed of microthin soft plastic inserts of variable thickness that are placed in the periphery of the cornea. Intrastromal corneal ring segments have been investigated as a means of improving vision in diseases such as keratoconus and pellucid marginal degeneration, and for refractive surgery to correct mild myopia and astigmatism following penetrating keratoplasty (PK).

MEDICAL CRITERIA
BlueCHiP for Medicare and Commercial Products
Implantation of intrastromal corneal ring segments may be considered medically necessary for the treatment of keratoconus in patients 21 years of age or older who meet the following criteria:

- The patient has experienced a progressive deterioration in their vision, such that they can no longer achieve adequate functional vision with contact lenses or spectacles; AND
- Corneal transplantation is the only alternative to improve their functional vision; AND
- The patient has a clear central cornea with a corneal thickness of 450 microns or greater at the proposed incision site.

PRIOR AUTHORIZATION
BlueCHiP for Medicare and Commercial Products
Prior authorization is required for BlueCHiP for Medicare and recommended for Commercial products and is obtained via the online tool for participating providers for the treatment of keratoconus. See the Related Policies section.

POLICY STATEMENT
BlueCHiP for Medicare and Commercial Products
Implantation of intrastromal corneal ring segments may be considered medically necessary for the treatment of keratoconus when the medical criteria above have been met.

Implantation of intrastromal corneal ring segments is not covered and is a contract exclusion as a treatment of myopia.

Implantation of intrastromal corneal ring segments is considered not medically necessary for all other conditions due to insufficient peer-reviewed scientific literature proving the efficacy of the procedure.

COVERAGE
Benefits may vary between groups/contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable surgery benefits/coverage and limitations of benefits/coverage when services are not medically necessary.

BACKGROUND
Intrastromal corneal ring segments are composed of microthin soft plastic inserts of variable thickness that are placed in the periphery of the cornea. They are inserted through an incision made in the cornea, into which channels have been created by rotating a lamellar dissector or by using a femtosecond laser. One or 2 corneal implant segments are implanted in each channel, and various implants with a range of implant
thicknesses are available for different degrees of correction. They affect refraction in the eye by physically changing the shape of the cornea (flattening the front of the eye), thereby correcting the irregular corneal shape and restoring a degree of functional vision. If required, the implants can be removed or replaced at a later date. ICRS have been investigated as a means of improving vision in diseases such as keratoconus and pellucid marginal degeneration, and for refractive surgery to correct mild myopia and astigmatism after penetrating keratoplasty.

**Keratoconus**

Keratoconus is a progressive bilateral dystrophy that is characterized by paracentral steepening and stromal thinning that impairs visual acuity. Initial treatment often consists of hard contact lenses. A penetrating keratoplasty (i.e., corneal grafting) was traditionally considered the next line of treatment in patients who developed intolerance to contact lenses. While visual acuity is typically improved with keratoplasty, perioperative complications are an associated risk; long-term topical steroid use is required; and endothelial cell loss occurs over time, which is a particular concern in younger patients. As an alternative, a variety of keratorefractive procedures have been attempted, broadly divided into subtractive and additive techniques. Subtractive techniques include photorefractive keratectomy or laser in situ keratomileusis (LASIK), but in general, results of these techniques have been poor. In deep anterior lamellar keratoplasty, pathologic corneal stromal tissue is selectively removed to the level of the Descemet membrane; followed by transplantation of a donor graft. Implantation of intrastromal corneal ring segments represents an additive technique in which the implants are intended to reinforce the cornea, prevent further deterioration, and potentially obviate the need for a penetrating keratoplasty.

**Pellucid Marginal Degeneration**

Pellucid marginal degeneration is a noninflammatory progressive degenerative disease, typically characterized by bilateral peripheral thinning (ectasia) of the inferior cornea. Deterioration of visual function results from the irregular astigmatism induced by asymmetric distortion of the cornea, and visual acuity typically cannot be restored by using spherocylindrical lenses. Rigid gas permeable contact lenses may be used to treat pellucid marginal degeneration. Intracorneal ring segment implantation, crescentic lamellar keratoplasty, penetrating keratoplasty, and corneal wedge excision have also been proposed.

**Myopia**

In myopia, intrastromal inserts correct myopia by flattening the center of the cornea and represent an alternative to LASIK and other refractive surgeries. The proposed advantages of the intrastromal corneal rings are that their insertion does not affect the central cornea, and thus, their effect is not related to the healing process in the cornea. No corneal tissue is removed, and the implants may be removed or replaced. However, mild myopia is effectively treated with either spectacles or contact lenses.

The evidence for ICRS in individuals who have keratoconus, pellucid marginal degeneration, and astigmatism following PK includes primarily single-institution case series. For eyes with keratoconus there are number of prospective series that have shown improvement in visual function from baseline to posttreatment, although data on net health outcome in the long-term are limited.

Although questions remain about the impact if ICRS on long-term health outcomes, the risk of adverse events is decreased compared with the existing alternative (corneal transplant), and there is a potential (as yet unproven) to delay the need for the more invasive procedure. Therefore, the use of intrastromal corneal ring segments may be considered medically necessary in patients who meet the U.S. Food and Drug Administration (FDA) humanitarian device exemption criteria for use of this device.

For pellucid marginal degeneration and astigmatism following PK, there are very limited data at this time. The evidence is insufficient to determine the effects of the technology on health outcomes.
There is insufficient evidence to evaluate health outcomes in patients with conditions other than keratoconus. Therefore, intrastromal corneal ring segments in this population are considered not medically necessary.

**CODING**

**BlueCHiP for Medicare and Commercial Products**
The following CPT code is considered medically necessary when the medical criteria above are met:

**65785** Implantation of intrastromal corneal ring segments

**RELATED POLICIES**
Preauthorization via Web-Based Tool for Procedures

**PUBLISHED**
Provider Update, December 2017
Provider Update, September 2016
Provider Update, January 2016
Provider Update, July 2010

**REFERENCES**


This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member’s subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.